

CITATION REPORT

List of articles citing

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

DOI: 10.1056/nejmoa1316366

New England Journal of Medicine, 2014, 370, 1483-93.

Source: <https://exaly.com/paper-pdf/58960125/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1212	Research roundup. 2014 , 12, S5-S6		
1211	Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. 2014 , 28, 445-51		51
1210	Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline. 2014 , 28, 529-34		5
1209	Review of Current Dengue Treatment and Therapeutics in Development. 2014 , s8,		3
1208	CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfecting adults. 2014 , 25, 311-20		6
1207	Barrier to resistance: lessons from 2 direct-acting hepatitis C virus inhibitors, MK-5172 and Sofosbuvir. 2014 , 59, 1675-7		2
1206	Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?. 2014 , 12, 763-73		40
1205	Sofosbuvir as backbone of interferon free treatments. 2014 , 46 Suppl 5, S212-20		19
1204	The future of dual therapy for hepatitis C virus. 2014 , 9, 905-912		1
1203	[Treatment of hepatitis C: what is known?]. 2014 , 55, 1419-26		4
1202	Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy. 2014 , 14, 503		3
1201	Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. 2014 , 61, S98-S107		25
1200	"Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic?. 2014 , 6, 1893-907		8
1199	Actualizaci3n en el tratamiento de la hepatitis C. 2014 , 11, 4103-4111		
1198	Optimal Management of HIV-HCV Coinfection. 2014 , 13, 295-303		
1197	HCV: Fibrosis Progression. 2014 , 13, 265-272		1
1196	Quasispecies and Drug Resistance. 2014 , 1-22		

1195	Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. 2014 , 7, 387-98	18
1194	Antiviral Agents. 2014 , 176-176	
1193	Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. 2014 , 161, 634-8	62
1192	[Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Simeprevir-benefit assessment according to § 35a SGB V the Federal Joint Committee]. 2014 , 52, 1495-9	
1191	Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. 2014 , 46 Suppl 5, S197-205	6
1190	Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C. 2014 , 52, 1185-1197	5
1189	Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? AuthorsReply. 2014 , 40, 984-5	
1188	Letter: chronic Salmonella typhi carrier status and gall-bladder cancer. 2014 , 39, 1439-40	
1187	Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. 2014 , 15, 2609-22	17
1186	Letter: single liver stiffness measurement predicts liver-related mortality in chronic hepatitis C. 2014 , 39, 1438-9	2
1185	Viral hepatitis: new hepatitis C therapies-a medical pick and mix. 2014 , 11, 329	
1184	New all-oral HCV therapies for genotype 1: A final good-bye to interferon. 2014 , 3, 137-140	2
1183	Optimal Management of HCV Transplant Patients. 2014 , 13, 304-313	
1182	A practical guide for antiviral therapy of chronic Hepatitis C. 2014 , 21, 221-230	6
1181	Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. 2014 , 61, S120-31	57
1180	Management of acute and chronic HCV infection in persons with HIV coinfection. 2014 , 61, S108-19	15
1179	Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. 2014 , 34, 1341-54	25
1178	Daclatasvir for the treatment of hepatitis C virus infection. 2014 , 8, 725-38	6

1177	HCV Triple Therapy is Equally effective in African-Americans and Non-African-Americans. 2014 , 1, 319-325		1
1176	Hepatitis C genotype 1. 2014 , 27, 535-9		
1175	Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs. 2014 , 46 Suppl 5, S206-11		6
1174	Reply to: "Cost-effectiveness of upcoming treatments for hepatitis C: we need to get the models right". 2014 , 61, 454-5		
1173	Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. 2014 , 61, 435-8		32
1172	Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?. 2014 , 107, 119-24		32
1171	Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. <i>New England Journal of Medicine</i> , 2014 , 370, 1879-88	59.2	975
1170	Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. <i>New England Journal of Medicine</i> , 2014 , 370, 1889-98	59.2	1402
1169	Therapy of hepatitis C--back to the future. <i>New England Journal of Medicine</i> , 2014 , 370, 2043-7	59.2	91
1168	The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. 2014 , 46 Suppl 5, S186-96		53
1167	Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase. 2014 , 33, 1728-35		32
1166	Hepatitis C beware--the end is nigh. 2014 , 384, 1557-60		18
1165	Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents. 2014 , 58, 5386-94		28
1164	Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C. 2014 , 61, S91-7		21
1163	Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus. 2014 , 66, 1653-66		18
1162	Optimal Management of the Hepatitis C Patient: Review of the AASLD/IDSA Guidelines. 2014 , 13, 314-320		
1161	Hepatitis C in African Americans. 2014 , 109, 1576-84; quiz 1575, 1585		30
1160	All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. 2014 , 384, 1597-605		278

1159	Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. 2014 , 15, 1837-48		6
1158	New therapies for hepatitis C: considerations in patients with renal impairment. 2014 , 74, 1307-13		4
1157	Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity. 2014 , 8, 352-64		1
1156	Antiviral treatment of hepatitis C. 2014 , 348, g3308		154
1155	Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance. 2014 , 88, 11886-98		61
1154	Decade in review-HCV: hepatitis C therapy-a fast and competitive race. 2014 , 11, 644-5		7
1153	Hepatitis C virus and interferon type III (interferon- β /interleukin-28B and interferon- λ): genetic basis of susceptibility to infection and response to antiviral treatment. 2014 , 20, 1237-45		12
1152	Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. 2014 , 88, 12098-111		57
1151	Treatment of hepatitis C: perspectives. 2014 , 44, 449-54		11
1150	Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects. 2014 , 54, 1290-8		20
1149	Hepatitis C: Treatment triumphs. 2014 , 510, 43-4		32
1148	Treating hepatitis C in lower-income countries. <i>New England Journal of Medicine</i> , 2014 , 370, 1869-71	59.2	64
1147	Sofosbuvir: a review of its use in patients with chronic hepatitis C. 2014 , 74, 1127-46		57
1146	Sofosbuvir (Sovaldi) for the treatment of hepatitis C. 2014 , 7, 555-66		18
1145	Therapy for hepatitis C--the costs of success. <i>New England Journal of Medicine</i> , 2014 , 370, 1552-3	59.2	99
1144	QUEST for a cure for hepatitis C virus: the end is in sight. 2014 , 384, 381-3		6
1143	Update on hepatitis C virus resistance to direct-acting antiviral agents. 2014 , 108, 181-91		159
1142	Future therapy of portal hypertension in liver cirrhosis - a guess. 2014 , 6, 95		16

1141	Implementation and evaluation of a multicomponent quality improvement intervention to improve efficiency of hepatitis C screening and diagnosis. 2014 , 40, 351-7	15
1140	The clinical management of HCV in the HIV-infected patient. 2015 , 20, 457-67	2
1139	Hepatitis C: from discovery to eradication. 2014 , 12, 26-35	2
1138	Targeting gap junction intercellular communication as a potential therapy for HCV-related carcinogenesis. 2014 , 9, 679-692	
1137	The dawn of a new era in the treatment of HCV infection: A view from the USA. 2014 , 4, 107-108	
1136	[Cost-effective medical therapy of hepatitis C employing novel compensation models - pay for cure]. 2015 , 53, 1414-21	1
1135	Hepatitis C guidance: AASLD-IDSAs recommendations for testing, managing, and treating adults infected with hepatitis C virus. 2015 , 62, 932-54	968
1134	Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. 2015 , 62, 1037-46	132
1133	Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy. 2015 , 45, E115-21	35
1132	Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens. 2015 , 41, 497-520	130
1131	Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. 2015 , 35, 1923-33	24
1130	Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor. 2015 , 61-80	4
1129	Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. 2015 , 163, 215-23	304
1128	Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. 2015 , 163, 899-907	46
1127	Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection. 2015 , 4, 33-5	10
1126	Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. 2015 , 163, 809-17	68
1125	The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. 2016 , 21, 185-94	5
1124	Self-reported need for psychotherapy predicts interferon-induced depression in hepatitis C: stratification for interferon-free treatment. 2015 , 20, 501-6	2

1123	A new era of therapy for hepatitis C virus infection. 2015 , 28, 471-8	16
1122	Hepatitis C in a prison in the North East of England: what is the economic impact of the universal offer of testing and emergent medications?. 2016 , 38, e554-e562	2
1121	Hepatitis C □Therapie-Update. 2015 , 12, 7-16	
1120	Interferonfreie Therapie der Hepatitis C mit/ohne nukleosidischen Polymeraseinhibitor. 2015 , 10, 292-296	
1119	Therapie der Hepatitis C bei Patienten mit Zirrhose sowie vor und nach Lebertransplantation. 2015 , 10, 297-304	
1118	Therapie der Hepatitis C Virusinfektion. 2015 , 10, 61-72	
1117	Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. 2015 , 98, 394-402	12
1116	Resistance to direct-acting antiviral agents: clinical utility and significance. 2015 , 10, 381-9	20
1115	Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade. 2015 , 22, 481-8	7
1114	Treatment of hepatitis C in coinfecting patients. 2015 , 10, 1291-1305	
1113	Radiotherapy for liver tumors. 2015 , 2, 133-146	6
1112	Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. 2015 , 28, 1011-24	10
1111	Epidemiological trends among the population with chronic HCV infection in the Netherlands. 2016 , 21, 207-15	
1110	Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. 2015 , 42, 889-901	84
1109	Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list. 2015 , 28, 1345-9	15
1108	Current guidelines and prioritizing treatment of hepatitis C virus in HIV-infected patients. 2015 , 10, 323-9	5
1107	Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. 2015 , 121, 2874-82	53
1106	Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. 2015 , 62, 1013-23	39

1105	The hepatitis C revolution part 1: antiviral treatment options. 2015 , 28, 563-71	16
1104	Dermatitis induced by first-generation hepatitis C virus protease inhibitors. 2015 , 173, 311-2	3
1103	Hepatitis C virus infection in nonliver solid organ transplant candidates and recipients. 2015 , 20, 259-66	4
1102	Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. 2015 , 94, e690	71
1101	Harvoni (ledipasvir and sofosbuvir) for hepatitis C. 2015 , 40, 22-6	4
1100	The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. 2015 , 42, 286-95	74
1099	Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection. 2015 , 62, 1047-58	36
1098	Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. 2015 , 22, 861-70	64
1097	Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients. 2015 , 10, 337-47	11
1096	Recent advances in management of the HIV/HCV coinfecting patient. 2015 , 10, 981-997	4
1095	Hepatitis C virus-HIV-coinfecting patients and liver transplantation. 2015 , 20, 276-85	14
1094	The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches. 2015 , 28, 572-5	
1093	Kidney transplantation threshold in patients with hepatitis C: a decision analysis model. 2015 , 99, 829-34	2
1092	Chronic hepatitis. 296-307	
1091	Demographical, Viro-Immunological, Clinical and Therapeutical Characteristics of HIV-Infected Patients in an "Epidemiologically Unexplored" Region of Italy (Calabria Region): the CalabrHIV Cohort. 2015 , 7, e2015054	
1090	Changing the face of hepatitis C management - the design and development of sofosbuvir. 2015 , 9, 2367-74	20
1089	Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase. 2015 , 16, 18439-53	18
1088	Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. 2015 , 7, 1843-55	24

1087	Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. 2015 , 6, 114-9	10
1086	Sofosbuvir, a Significant Paradigm Change in HCV Treatment. 2015 , 3, 27-35	45
1085	Hepatitis C, disease and its management: a cost-effectiveness analysis of the new generation oral protease inhibitors. 2015 , 20, 827-33	2
1084	Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. 2015 , 7, 5018-39	51
1083	Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance. 2015 , 7, 5155-68	19
1082	Interferon-free combination therapies for the treatment of hepatitis C: current insights. 2015 , 7, 51-70	46
1081	Does herbal medicine reduce the risk of hepatocellular carcinoma?. 2015 , 21, 10598-603	6
1080	Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response. 2015 , 10, e0129053	55
1079	A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. 2015 , 10, e0133028	13
1078	Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. 2015 , 10, e0134395	64
1077	Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production. 2015 , 10, e0135232	5
1076	A Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3/4 Protein Exhibits Immunogenic Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine. 2015 , 10, e0142349	9
1075	Treatment guidelines for Hepatitis C in Spain. 2015 , 17, 37-47	2
1074	Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfecting patients are comparable with hepatitis C monoinfected patients. 2015 , 26, 293-6	3
1073	Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. 2015 , 2015, 159795	5
1072	An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. 2015 , 29, 19-34	59
1071	Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. 2015 , 2015, 852968	5
1070	The dollars and sense of chronic hepatitis C infection management. 2015 , 26, 119-21	1

1069	The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing. 2015 , 29, 46-8	4
1068	Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada. 2015 , 29, 125-9	4
1067	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. 2015 , 14, 477-486	1
1066	Viral Hepatitis. 2015 , 1439-1468.e7	4
1065	[Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment]. 2015 , 66, 131-3	
1064	Mexican Consensus on the Diagnosis and Management of Hepatitis C Infection. 2015 , 14, S7-S48	0
1063	Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. 2015 , 7, 1921-35	10
1062	[New Therapeutic Agent for Chronic Hepatitis C: Direct Acting Agent]. 2015 , 66, 5-9	1
1061	HCV cure for everyone or which challenges remain?. 2015 , 1, 55-58	3
1060	Hepatitis C [Overview and Update in Treatment. 2015 ,	
1059	Advances in HCV Therapy. 2015 ,	
1058	New Perspective in HCV Clinical and Economical Management of the Current and Future Therapies. 2015 ,	
1057	Hepatitis C treatment in patients on the liver transplant waiting list. 2015 , 20, 242-50	4
1056	Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. 2015 , 16, 739-48	11
1055	Provider Workforce Assessment in a Rural Hepatitis C Epidemic: Implications for Scale-up of Antiviral Therapy. 2015 , 6, 215-7	19
1054	Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals. 2015 , 29, 379-83	29
1053	Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection. 2015 , 37, 698-708	12
1052	Global policy and access to new hepatitis C therapies for people who inject drugs. 2015 , 26, 1064-71	12

1051	Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. 2015 , 70, 2322-9	23
1050	Hepatitis C Infection in the Elderly. 2015 , 60, 3170-80	29
1049	Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. 2015 , 61, 1495-502	126
1048	Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. 2015 , 61, 1471-8	42
1047	Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. 2015 , 75, 675-85	54
1046	Update in outpatient general internal medicine: practice-changing evidence published in 2014. 2015 , 128, 1065-9	1
1045	The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. 2015 , 50, 233-44	32
1044	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. 2015 , 149, 649-59	622
1043	Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. 2015 , 14, 1317-26	16
1042	Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. 2015 , 7, 11-20	2
1041	Pharmacological treatments for chronic hepatitis C liver disease: a network meta-analysis. 2015 ,	
1040	The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. 2015 , 10, 1363-77	43
1039	HCV Genotype 1 Infection: IFN-Free Treatment with Direct-Acting Antivirals Available in 2015. 2015 , 14, 260-266	
1038	Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV). 2015 , 32, 1117-27	24
1037	Hepatitis C: pay now or pay later?. 2015 , 10, 1285-1290	
1036	Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. 2015 , 6, 314-27	13
1035	[Hepatitis C]. 2015 , 157 Spec No 2, 86-9; quiz 90	
1034	Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone. 2015 , 59, 5503-10	25

1033	Effect of IL28B genotype on hepatitis B and C virus infection. 2015 , 14, 50-5	17
1032	Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection. 2015 , 49, 343-50	20
1031	The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners. 2015 , 11, 116-123	1
1030	Aza follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 1: Mitigating the genotoxic liability of an aniline metabolite. 2015 , 25, 1135-9	6
1029	Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients. 2015 , 35 Suppl 1, 65-70	16
1028	Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. 2015 , 70, 197-205	33
1027	Current and future HCV therapy: do we still need other anti-HCV drugs?. 2015 , 35 Suppl 1, 4-10	23
1026	Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma. 2015 , 42, 329-38	17
1025	Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in. 2015 , 21, 423-34	21
1024	Hepatitis C. 2015 , 385, 1124-35	365
1023	Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. 2015 , 49, 566-81	37
1022	Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. 2015 , 14, 473-84	8
1021	Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. 2015 , 41, 544-63	96
1020	Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. 2015 , 61, 1798-808	109
1019	Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. 2015 , 116, 10-6	95
1018	ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients. 2015 , 13, 295-304	4
1017	Bioactive nucleoside analogues possessing selected five-membered azaheterocyclic bases. 2015 , 97, 409-18	26
1016	Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. 2015 , 61, 1523-32	69

1015	Sofosbuvir for treatment of chronic hepatitis C. 2015 , 9, 161-73	22
1014	Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection. 2015 , 37, 243-67	24
1013	Successful treatment of hepatitis B and C: don't forget the liver!!!. 2015 , 128, 3-4	
1012	The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Childs class A cirrhosis. 2015 , 148, 762-70.e2; quiz e11-2	52
1011	Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. 2015 , 35, 1845-52	19
1010	Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease?. 2015 , 9, 559-66	13
1009	Shorter treatments for hepatitis C: another step forward?. 2015 , 385, 1054-5	4
1008	Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. 2015 , 385, 1107-13	131
1007	Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. 2015 , 148, 468-79	41
1006	Is widespread screening for hepatitis C justified?. 2015 , 350, g7809	31
1005	Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. 2015 , 477, 1-9	31
1004	Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. 2015 , 63, 30-7	31
1003	Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. 2015 , 30, 1057-64	4
1002	Revolution in hepatitis C antiviral therapy. 2015 , 113, 31-44	29
1001	Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C. 2015 , 16, 801-4	5
1000	Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. 2015 , 60, 1743-51	80
999	Cost-effectiveness of screening for hepatitis C in Canada. 2015 , 187, E110-E121	50
998	In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir. 2014 , 4, 137	18

997	Enhancing our understanding of current therapies for hepatitis C virus (HCV). 2015 , 12, 68-78	25
996	Sustained Virological Response and Hepatitis C-Related Cirrhosis: a World of Opportunities. 2015 , 14, 32-39	
995	FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function. 2015 , 141, 1311-9	8
994	Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. 2015 , 110, 1179-85	32
993	Regimens for Cirrhotic Patients. 2015 , 19, 657-67, vi	
992	Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient. 2015 , 90, 1294-7	10
991	The New Era of Interferon-Free Treatment of Chronic Hepatitis C. 2015 , 31, 290-6	14
990	Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population. 2015 , 25, 289-93	4
989	A pill a day keeps HCV away. 2015 , 15, 616-7	8
988	Management of HCV in the liver transplant setting. 2015 , 39 Suppl 1, S115-9	5
987	The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. 2015 , 8, 298-312	83
986	Chronic hepatitis B: A wave of new therapies on the horizon. 2015 , 121, 69-81	53
985	HCV targeting of patients with cirrhosis. 2015 , 63, 1015-22	42
984	Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. 2015 , 24, 1229-39	21
983	Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. <i>New England Journal of Medicine</i> , 2015 , 373, 714-25	59.2 337
982	Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. <i>New England Journal of Medicine</i> , 2015 , 373, 705-13	59.2 382
981	Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. 2015 , 149, 971-80.e1	67
980	Paritaprevir in patients with chronic hepatitis C genotype 1. 2015 , 10, 679-690	1

979	Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. 2015 , 15, 1049-1054	136
978	HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials. 2015 , 61, 1127-34	26
977	Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection. 2015 , 4, 593-605	4
976	Advances in Hepatitis C Treatment: At the Crossroads. 2015 , 11, 669-679	1
975	Ledipasvir/Sofosbuvir. 2015 , 50, 224-34	5
974	Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens. 2015 , 29, 329-37	9
973	Protocol 22: Acute and Chronic Hepatitis. 2015 , 180-187	
972	Management of HCV in cirrhosis-a rapidly evolving landscape. 2015 , 17, 443	3
971	Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naïve and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. 2015 , 15, 645-53	294
970	Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. 2015 , 9, 547-58	19
969	Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. 2015 , 63, 564-72	123
968	Faldaprevir for the treatment of genotype-1 hepatitis C virus. 2015 , 9, 277-88	2
967	Treatment of hepatitis C in difficult-to-treat patients. 2015 , 12, 284-92	60
966	From non-A, non-B hepatitis to hepatitis C virus cure. 2015 , 62, S87-99	231
965	Evaluation of the COBAS() AmpliPrep/COBAS() TaqMan() HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study. 2015 , 67, 67-72	17
964	[Treatment of hepatitis C]. 2015 , 56, 391-405	1
963	Novel interventions to prevent HIV and HCV among persons who inject drugs. 2015 , 12, 145-63	16
962	Cure of HCV related liver disease. 2015 , 35 Suppl 1, 71-7	20

961	EASL Recommendations on Treatment of Hepatitis C 2015. 2015 , 63, 199-236	942
960	Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. 2015 , 15, 19	118
959	First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. 2015 , 12, 37	11
958	Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals. 2015 , 4, 267-277	9
957	Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. 2015 , 62, 25-30	71
956	Noninvasive Markers of Fibrosis in the Assessment of Cirrhosis. 2015 , 39-47	
955	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. 2015 , 13, 1846-1853.e1	45
954	Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. 2015 , 63, 337-45	116
953	Hope for non-responders with hepatitis C virus and cirrhosis. 2015 , 15, 363-5	2
952	Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). 2015 , 15, 397-404	244
951	The ongoing debate of who to treat for chronic hepatitis C virus. 2015 , 175, 169-70	6
950	Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach. 2015 , 59, 3482-92	19
949	Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. 2015 , 313, 1736-44	103
948	Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy. 2015 , 75, 823-34	12
947	Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. 2015 , 62, 79-86	207
946	Mixed HCV infection and reinfection in people who inject drugs--impact on therapy. 2015 , 12, 218-30	68
945	Prevalence and management of chronic hepatitis C virus infection in women. 2015 , 99, 575-86	5
944	Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. 2015 , 162, 397-406	263

943	Management of post transplant hepatitis C in the direct antiviral agents era. 2015 , 9, 192-201	7
942	Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. 2015 , 313, 1232-9	171
941	HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. 2015 , 9, 424-30	29
940	Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice. 2015 , 50, 1145-51	26
939	Hepatitis C Virus: A European Perspective. 2015 , 44, 807-24	12
938	Editorial Commentary: Who is "Special" Now?. 2015 , 61, 826-8	
937	Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens. 2015 , 61, 974-7	8
936	Repurposing of HDAC inhibitors toward anti-hepatitis C virus drug discovery: teaching an old dog new tricks. 2015 , 7, 1367-71	6
935	Ledipasvir/sofosbuvir in chronic hepatitis C: a guide to its use in the EU. 2015 , 31, 289-295	2
934	Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies. 2015 , 75, 1981-92	33
933	Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study. 2015 , 8, 260	7
932	Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015. 2015 , 5, 221-38	16
931	Overtreating versus undertreating: what is the optimized treatment duration in HCV?. 2015 , 10, 1049-1056	
930	Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis. 2015 , 33, 613-23	13
929	Advances in hepatitis C therapies. 2015 , 16, 1929-43	2
928	Ledipasvir-sofosbuvir for hepatitis C genotype 4 infection. 2015 , 15, 993-995	8
927	Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. 2015 , 149, 1454-1461.e1	160
926	Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. 2015 , 62, 1004-12	48

925	Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. 2015 , 21, 1870-82	43
924	Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. 2015 , 59, 6807-15	35
923	Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients. 2015 , 15, 344	9
922	Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopenia and hypoalbuminaemia. 2015 , 35, 2358-62	14
921	[S3 guideline hepatitis C addendum]. 2015 , 53, 320-34	37
920	Regimens for Patients Coinfected with Human Immunodeficiency Virus. 2015 , 19, 689-706, vi-vii	1
919	Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort. 2015 , 53, 644-54	11
918	Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern. 2015 , 34, 1666-74	24
917	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. 2015 , 64, 1824-33	99
916	Asunaprevir (BMS-650032) for the treatment of hepatitis C virus. 2015 , 13, 1307-17	4
915	Natural prevalence of resistance-associated variants in hepatitis C virus NS5A in genotype 3a-infected people who inject drugs in Germany. 2015 , 70, 43-45	13
914	Chronic Kidney Disease and Related Long-Term Complications After Liver Transplantation. 2015 , 22, 404-11	29
913	What does the pharmacological future of treating chronic hepatitis C look like?. 2015 , 8, 605-22	4
912	Management of direct-acting antiviral agent failures. 2015 , 63, 1511-22	62
911	Significant publications on infectious diseases pharmacotherapy in 2014. 2015 , 72, 1380-92	7
910	Alcoholic liver disease: Clinical and translational research. 2015 , 99, 596-610	28
909	High-resolution genetic profile of viral genomes: why it matters. 2015 , 14, 62-70	10
908	Direct-acting antivirals for hepatitis C treatment: effectiveness versus cost-effectiveness. 2015 , 10, 929-932	3

907	Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA. 2015 , 53, 3039-41	11
906	Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. 2015 , 17, 462	1
905	Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. 2015 , 44, 825-43	16
904	Hepatitis C Management and the Infectious Diseases Pharmacist. 2015 , 61, 1201-2	7
903	Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection. 2015 , 9, 1483-94	7
902	The safety of daclatasvir for the treatment of hepatitis C. 2015 , 14, 1787-97	2
901	European Code against Cancer 4th Edition: Infections and Cancer. 2015 , 39 Suppl 1, S120-38	30
900	Hepatitis C treatment and quality of life - You can't always get what you want, but you might get what you need. 2015 , 63, 300-2	7
899	Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin. 2016 , 62, 527-8	1
898	Daclatasvir for the treatment of chronic hepatitis C. 2015 , 16, 2679-88	6
897	Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. 2016 , 62, 440-447	30
896	Emerging treatments for chronic hepatitis C. 2015 , 114, 204-15	32
895	New era for management of chronic hepatitis C virus using direct antiviral agents: A review. 2015 , 6, 301-10	28
894	Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C WORTHY): a randomised, open label phase 2 trial. 2015 , 385, 1075-86	254
893	Controlling hepatitis C with simeprevir. 2015 , 15, 2-4	1
892	Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. 2015 , 62, 1008-14	114
891	PRO view: treat to prevent recurrence of HCV. 2015 , 35, 5-6	1
890	New kids on the block--step by step to an ideal HCV therapy. 2015 , 385, 1050-2	9

889	Hepatitis C virus-associated cancer. 2015 , 10, 345-70	66
888	Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. 2015 , 61, 471-80	67
887	Challenges to liver transplantation and strategies to improve outcomes. 2015 , 148, 307-23	163
886	Viral entry inhibition: too late for hepatitis C, but promising for other viral infections. 2015 , 64, 362-4	3
885	Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection. 2015 , 9, 21-30	4
884	Sofosbuvir for the treatment of hepatitis C virus infection. 2015 , 187, 203-204	3
883	Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. 2015 , 22, 469-80	6
882	Hepatitis C Virus. 2016 , 1313-1345	
881	Direct Acting Antivirals Which Is Effective in Pan-genotypic Chronic Hepatitis C Patients with or without Liver Cirrhosis. 2016 , 68, 229	
880	An insight into the molecular characteristics of hepatitis C virus for clinicians. 2016 , 37, 483-91	3
879	Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study. 2016 , 22, 863-71	1
878	Australian recommendations for the management of hepatitis C virus infection: a consensus statement. 2016 , 204, 268-72	49
877	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. 2016 , 2016, 4385643	14
876	Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016?. 2017 , 9, e2017003	8
875	Liver transplantation for viral hepatitis in 2015. 2016 , 22, 1570-81	30
874	[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1]. 2016 , 67, 127-31	1
873	A Protease Inhibitor with Induction Therapy with Natural Interferon- β in Patients with HCV Genotype 1b Infection. 2016 , 17, 350	1
872	Anti-Hepatitis Virus Agents. 2016 , 239-270	

871	The Australasian Hepatology Association consensus guidelines for the provision of adherence support to patients with hepatitis C on direct acting antivirals. 2016 , 10, 2479-2489	6
870	Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection. 2016 , 8, 75-80	7
869	New approaches in the treatment of hepatitis C. 2016 , 22, 1421-32	84
868	Real-World Drug Costs of Treating Hepatitis C Genotypes 1-4 with Direct-Acting Antivirals: Initiating Treatment at Fibrosis 0-2 and 3-4. 2016 , 22, 1437-1445	2
867	Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective. 2016 , 12, 861-72	8
866	Advances in hepatitis C therapy: What is the current state - what comes next?. 2016 , 8, 139-47	75
865	Intestinal Fibrosis and Liver Fibrosis: Consequences of Chronic Inflammation or Independent Pathophysiology?. 2016 , 1, 41-49	12
864	Combinations of siRNAs against La Autoantigen with NS5B or hVAP-A Have Additive Effect on Inhibition of HCV Replication. 2016 , 2016, 9671031	5
863	Recent Advances in Antiviral Therapy for Chronic Hepatitis C. 2016 , 2016, 6841628	39
862	Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. 2016 , 22, 8050-9	33
861	Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment. 2016 , 8, 91	16
860	Hepatitis C virus: Promising discoveries and new treatments. 2016 , 22, 6393-401	15
859	In Vitro Study on Anti-Hepatitis C Virus Activity of Spatholobus suberectus Dunn. 2016 , 21,	19
858	Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable polymorphism. 2017 , 5, 208-212	4
857	Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents. 2016 , 11, e0155869	78
856	Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. 2016 , 11, e0155934	26
855	Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis. 2016 , 11, e0157832	20
854	Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. 2016 , 11, e0164691	46

853	Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. 2016 , 16, e40959	48
852	Anti-hepatitis C virus drugs and kidney. 2016 , 8, 1343-1353	12
851	Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer?. 2016 , 50, 252-7	5
850	Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. 2016 , 30, 261-6	23
849	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. 2016 , 14, 1821-1830.e6	46
848	Successful therapy with Ledipasvir/Sofosbuvir for hepatitis C reactivation in a hematopoietic stem cell transplant recipient. 2016 , 57, 2693-5	
847	Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens. 2016 , 64, 386-93	34
846	Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. 2016 , 23, 857-865	41
845	Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. 2016 , 6, 119-45	18
844	Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. 2016 , 63, 1112-9	56
843	Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin. 2016 , 23, 227-31	
842	The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. 2016 , 36, 42-8	43
841	Eighteen- to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission. 2016 , 23, 274-81	7
840	New prospects for the treatment and prevention of hepatitis C in children. 2016 , 28, 93-100	19
839	Directly acting antivirals for hepatitis C virus arrive in HIV/hepatitis C virus co-infected patients: from mind the gap to where's the gap? 2016 , 30, 975-89	5
838	Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. 2016 , 23, 217-26	40
837	High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens. 2016 , 23, 667-76	5
836	Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. 2016 , 36, 505-14	14

835	The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. 2016 , 36, 971-6	28
834	Host genetic variants influencing the clinical course of hepatitis C virus infection. 2016 , 88, 185-95	26
833	Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). 2016 , 64, 360-9	142
832	Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy. 2016 , 88, 1776-84	2
831	Healing livers, saving lives: Hepatitis C screening in an era of cure. 2016 , 29, 20-8	
830	Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. 2016 , 31, 1323-9	21
829	Pricey pills for an even pricier problem. 2016 , 122, 840-1	
828	Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection. 2016 , 36, 562-74	8
827	Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. 2016 , 23, 623-30	31
826	Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort. 2016 , 91, E335-40	13
825	Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. 2016 , 18, 22	13
824	Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists. 2016 , 36, 203-17	19
823	Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. 2016 , 60, 5368-78	67
822	Hepatitis C virus resistance to the new direct-acting antivirals. 2016 , 12, 1197-209	36
821	Hepatitis C-A clinical review. 2016 , 88, 1844-55	27
820	Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. 2016 , 95, e2702	31
819	Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. 2016 , 43, 1276-92	103
818	Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. 2016 , 22, 214-217	29

817	Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin. 2016 , 22, 692-9	5
816	Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C. 2016 , 31, 1628-37	8
815	Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. 2016 , 31, 1851-1859	4
814	Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients. 2017 , 22, 481-493	55
813	Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies. 2016 , 21, 679-687	8
812	Ledipasvir and sofosbuvir for HCV infection in patients coinfecting with HBV. 2016 , 21, 605-609	39
811	Why is viral eradication so important in patients with HCV-related cirrhosis?. 2017 , 22, 1-12	6
810	Genotype 1 hepatitis C virus and the pharmacist's role in treatment. 2016 , 73, 764-74	17
809	Drug Interactions Associated with HIV and HCV Medications. 2016 , 8, 404-415	
808	Molecular Detection and Characterization of Hepatitis C Virus. 2016 , 430-448	
807	Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis. 2017 , 22, 369-379	11
806	Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. 2016 , 4, E605-E614	59
805	Treatment of chronic hepatitis C in patients with cirrhosis. 2016 , 32, 143-51	10
804	The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis. 2016 , 5, 110	6
803	Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. 2016 , 63, 1455-70	32
802	[Treatment of hepatitis C before and after liver transplantation]. 2016 , 39, 344-51	1
801	Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. 2016 , 19, 326-34	27
800	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. 2016 , 10, 681-701	60

799	Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?. 2016 , 36, 661-72	12
798	Hepatitis por el virus C. 2016 , 12, 484-493	
797	A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. 2016 , 10, 947-955	15
796	Pharmacologic Therapies in Gastrointestinal Diseases. 2016 , 100, 827-50	15
795	Handbook of Hepatitis C. 2016 ,	1
794	Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C. 2016 , 55, 1337-1351	55
793	Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective. 2016 , 7, 391-402	9
792	Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment. 2016 , 10, 624-31	11
791	Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. 2016 , 34, 1787-94	241
790	JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2. 2016 , 46, 129-65	48
789	An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens. 2016 , 111, 808-16	75
788	Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. 2016 , 19, 795-805	16
787	Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus. 2016 , 60, 3786-93	29
786	Improved Survival Among all Interferon- β -Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders. 2016 , 61, 1744-56	3
785	Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. 2016 , 111, 845-51	10
784	Prevention and management of treatment failure to new oral hepatitis C drugs. 2016 , 17, 1215-23	42
783	Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States. 2016 , 62, 1290-1296	36
782	APASL consensus statements and recommendation on treatment of hepatitis C. 2016 , 10, 702-26	155

781	Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. 2016 , 63, 291-9	44
780	Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. 2016 , 13, 338-51	122
779	Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies. 2016 , 494, 236-47	14
778	Challenges in Special Populations: HIV/HCV Coinfection, Liver Transplantation and Patients with End-Stage Renal Disease. 2016 , 34, 317-26	9
777	When and How to Treat HCV Infection with the New Antivirals before or after Liver Transplantation. 2016 , 32, 258-262	3
776	Analytical performance of the VERIS MDx system HCV assay for detecting and quantifying HCV RNA. 2016 , 84, 7-11	6
775	Management of HCV-Associated Liver Cirrhosis. 2016 , 32, 96-104	5
774	Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C. 2016 , 16, 659-665	6
773	Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. 2016 , 1, 97-104	65
772	Safety of direct antiviral agents in the management of hepatitis C. 2016 , 15, 1643-1652	24
771	Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016 , 41, 478-85	2.2 20
770	2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. 2016 , 59, 7311-51	29
769	Global genotype distribution of hepatitis C viral infection among people who inject drugs. 2016 , 65, 1094-1103	51
768	Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease. 2016 , 138, 11850-9	44
767	Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. 2016 , 122, 1312-37	629
766	Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. 2016 , 10, 789-98	13
765	Chronic Hepatitis C Infection in Children. 2016 , 63, 173-94	10
764	A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. 2016 , 30, 160-8	47

763	Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. 2016 , 23, 80-8	14
762	HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. 2016 , 36, 488-502	4
761	Why I do not treat patients for mild disease. 2016 , 36 Suppl 1, 13-20	4
760	HCV novel therapeutic regimens in Wonderland: A budget impact analysis in the Lombardy Region. 2016 , 48, 1200-7	3
759	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. 2016 , 151, 1131-1140.e5	166
758	Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. 2016 , 63, 1405-1411	78
757	Sofosbuvir plus ledipasvir for recurrent hepatitis C in liver transplant recipients. 2016 , 22, 1536-1543	42
756	Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C. 2016 , 19, 544-51	31
755	Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01). 2016 , 63, 1320-1324	60
754	Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. 2016 , 64, 1049-56	91
753	Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES. 2016 , 44, 728-37	10
752	Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. 2016 , 64, 1893-1899	52
751	Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1. 2016 , 44, 738-46	10
750	Hepatitis C Management in Patients with Hepatitis C and HIV Co-infection. 2016 , 15, 158-166	
749	New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). 2016 , 15, 85-100	15
748	Pioneering a Global Cure for Chronic Hepatitis C Virus Infection. 2016 , 167, 12-15	8
747	Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis. 2016 , 61, 3108-3117	8
746	Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. 2016 , 65, S109-S119	43

745	Second generation direct-acting antivirals - Do we expect major improvements?. 2016 , 65, S130-S142		28
744	Diagnostics in hepatitis C: The end of response-guided therapy?. 2016 , 65, S67-S81		19
743	Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. 2016 , 63, 1042-1048		45
742	Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. 2016 , 23, 496-505		31
741	Effect of Registries and Cohort Studies on HCV Treatment. 2016 , 151, 387-90		8
740	Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. 2016 , 26, 408-434		32
739	Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. 2016 , 29, 1257-1265		9
738	Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals. 2016 , 91, 341-347		20
737	Drug-Induced Lung Injury in a Liver Transplant Patient Treated With Sofosbuvir. 2016 , 48, 2515-2518		2
736	Management of Direct-Acting Antiviral Failures in Chronic Hepatitis C Infection. 2016 , 15, 296-306		1
735	Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016 , 41, 727-729	2.2	3
734	Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response. 2016 , 6, 35410		5
733	[Costs of a guideline-based treatment of patients with chronic hepatitis C in the era of interferon-free treatment]. 2016 , 54, 760-9		7
732	Host Genetics and Responses to Antiviral Therapy in Chronic Hepatitis C. 2016 , 225-241		
731	A case of hepatitis C related cirrhosis with genotype 1b relapsed after combination therapy with Sofosbuvir and Ledipasvir. <i>Acta Hepatologica Japonica</i> , 2016 , 57, 391-396	0.3	1
730	Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. 2016 , 13, e1002032		157
729	Management of hepatitis C genotype 4 in the directly acting antivirals era. 2016 , 3, e000112		10
728	On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. 2016 , 21, 541-546		6

727	Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials. 2016 , 3, e000056	16
726	The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV). 2016 , 95, e5066	7
725	Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. 2016 , 95, e4151	56
724	Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. 2016 , 95, e4243	13
723	Cascade of Care for Hepatitis C Virus Infection Within the US Veterans Health Administration. 2016 , 106, 353-8	47
722	Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case. 2016 , 23, 767-79	23
721	Czł: Wytyczne postępowania w hemofilii A i B niepowikłanej inhibitorem czynnika VIII i IX (wydanie zaktualizowane). 2016 , 47, 86-114	4
720	Management of HCV Infection. 2016 , 61-78	
719	[Chronic Hepatitis C - Therapeutic Options in 2016]. 2016 , 158 Suppl 1, 54-7	1
718	Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. 2016 , 151, 457-471.e5	170
717	Quantification of sofosbuvir and ledipasvir in human plasma by UPLC-MS/MS method: Application to fasting and fed bioequivalence studies. 2016 , 1028, 63-70	42
716	Management of Neurologic Manifestations in Patients with Liver Disease. 2016 , 18, 37	7
715	From current status to optimization of HCV treatment: Recommendations from an expert panel. 2016 , 48, 995-1005	12
714	Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir. 2016 , 63, 528-31	11
713	Hepatitis C virus treatment update [A new era of all-oral HCV treatment. 2016 , 3, 153-160	10
712	Treatment of hepatitis C before and after liver transplantation. 2016 , 39, 344-351	
711	Age-dependent changes in extracellular matrix turnover: An under evaluated issue in the approach to chronic liver diseases. 2016 , 64, 13-5	3
710	Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study. 2016 , 16, 45	17

709	Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. 2016 , 11, 24	83
708	(Z)-3,5,4-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression. 2016 , 76, 4887-96	19
707	Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. 2016 , 22, 846-852	23
706	Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. 2016 , 151, 501-512.e1	169
705	A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. 2016 , 63, 634-43	28
704	Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. 2016 , 31, 1168-76	33
703	Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190. 2016 , 23, 644-51	2
702	Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies. 2016 , 23, 780-8	32
701	Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. 2016 , 18, 326-32	38
700	Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial. 2016 , 5, 113-24	2
699	Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation. 2016 , 16, 1474-9	158
698	Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. 2016 , 43, 674-96	107
697	Comparative effectiveness of ledipasvir/sofosbuvir + ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in 6961 genotype 1 patients treated in routine medical practice. 2016 , 44, 400-10	58
696	Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with hepatitis C virus genotype 1b. 2016 , 46, 1311-1320	7
695	Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. 2016 , 64, 19-28	53
694	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. 2016 , 71, 739-50	12
693	A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients. 2016 , 47, 184-94	7
692	Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. 2016 , 16, 459-64	82

691	Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?. 2016 , 14, 41-56	4
690	Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. 2016 , 10, 21-36	8
689	Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. 2016 , 64, 790-9	53
688	Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. 2016 , 48, 251-261	11
687	New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. 2016 , 9, 287-302	27
686	Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. 2016 , 1008, 255-259	62
685	Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity. 2016 , 57, 82-8	20
684	L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. 2016 , 213, 1240-7	76
683	[Hepatitis C infection: Therapeutic strategies]. 2016 , 45, 495-508	1
682	Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. 2016 , 63, 437-44	53
681	Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. 2016 , 36 Suppl 1, 47-57	174
680	Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective. 2016 , 34, 741-50	11
679	Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. 2016 , 12, 353-61	13
678	In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir. 2016 , 60, 1847-1853	60
677	Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. 2016 , 64, 1224-31	344
676	Sofosbuvir and ledipasvir for HIV/HCV co-infected patients. 2016 , 17, 743-9	10
675	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. 2016 , 62, 1228-1234	19
674	Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C. 2016 , 15, 549-57	2

673	Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. 2016 , 65, 33-39	86
672	Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice. 2016 , 213, 62-68	7
671	Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. 2016 , 34, 551-67	65
670	Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. 2016 , 59, 841-53	24
669	Health Beliefs and Co-morbidities Associated with Appointment-Keeping Behavior Among HCV and HIV/HCV Patients. 2016 , 41, 30-7	5
668	Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection. 2016 , 14, 156-64.e3	47
667	Ideal oral combinations to eradicate HCV: The role of ribavirin. 2016 , 64, 215-25	34
666	Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. 2016 , 62, 280-288	41
665	Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. 2016 , 64, 292-300	34
664	Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. 2016 , 64, 301-307	125
663	The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. 2016 , 64, 486-504	337
662	Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. 2016 , 64, 234-8	75
661	Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct-Acting Antivirals: A Systematic Review and Meta-Analysis. 2016 , 20, 58-66	13
660	Efficacy and safety of telaprevir with pegylated interferon α -2a and ribavirin in Japanese patients. 2017 , 47, 514-521	4
659	Safety and efficacy of faldaprevir in combination with pegylated interferon α -2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection. 2017 , 47, E142-E151	
658	Hepatitis C Virus Infection: A New Era. 2017 , 247-254	
657	A systematic model improves hepatitis C virus birth cohort screening in hospital-based primary care. 2017 , 24, 477-485	25
656	Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. 2017 , 66, 1697-1708	164

655	Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment. 2017 , 7, 41660	19
654	Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. 2017 , 32, 1436-1442	26
653	Antiviral therapies for managing viral hepatitis in lymphoma patients. 2017 , 18, 363-376	9
652	Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. 2017 , 55, 1131-1139	15
651	Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection. 2017 , 152, 1366-1371	35
650	Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. 2017 , 52, 986-991	24
649	Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. 2017 , 89, 1248-1254	37
648	Hepatitis C Virus and Interferon-Free Antiviral Therapeutics Revolution: Implications for Pakistan. 2017 , 30, 252-257	7
647	Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. 2017 , 23, 198-206	20
646	US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection. 2017 , 37, 317-326	8
645	Electrophysiological Adverse Effects of Direct Acting Antivirals in Patients With Chronic Hepatitis C. 2017 , 57, 924-930	8
644	Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir. 2017 , 51, 543-547	6
643	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. 2017 , 15, 945-949.e1	18
642	Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting. 2017 , 74, S1-S9	2
641	Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfecting with HIV and HCV genotype-1: a Phase III, open-label study. 2017 , 11, 188-198	2
640	Augmentation of hepatitis C virus-specific immunity and sustained virologic response. 2017 , 24, 742-749	22
639	Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. 2017 , 45, 1201-1212	43
638	INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience. 2017 , 52, 585-588	9

637	Future Paradigms of HCV Management with Resistance Testing. 2017 , 16, 1-11	1
636	A European multicentre study on the comparison of HCV viral loads between VERIS HCV assay and COBAS TaqMan HCV Test and RealTime HCV Assay. 2017 , 90, 18-25	4
635	Current therapy for chronic hepatitis C: The role of direct-acting antivirals. 2017 , 142, 83-122	111
634	Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays. 2017 , 89, 51-56	5
633	Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. 2017 , 140, 151-157	5
632	Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein. 2017 , 114, 2018-2023	18
631	Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. 2017 , 66, 2008-2012	26
630	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. 2017 , 65, 1810-1822	64
629	Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study. 2017 , 66, 1123-1129	38
628	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. 2017 , 66, 1138-1148	131
627	Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions. 2017 , 6, 147-163	9
626	Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. 2017 , 11, 593-601	4
625	Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects. 2017 , 61,	24
624	Colorectal cancer diagnosed during pregnancy: systematic review and treatment pathways. 2017 , 29, 743-753	25
623	Hepatitis Viruses and Hepatoma. 2017 , 1-6	1
622	Influence of genetic variations in the SOD1 gene on the development of ascites and spontaneous bacterial peritonitis in decompensated liver cirrhosis. 2017 , 29, 800-804	5
621	Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. 2017 , 37, 635-646	17
620	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. 2017 , 49, 731-741	14

619	Updates on hepatitis C virus therapy in the direct-acting antiviral era. 2017 , 33, 115-119	6
618	The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis. 2017 , 29, 759-766	10
617	Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era. 2017 , 4, 174-185	31
616	Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. 2017 , 5, E97-E108	14
615	Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration. 2017 , 29, 781-785	3
614	Endoscopic variceal ligation combined with argon plasma coagulation versus ligation alone for the secondary prophylaxis of variceal bleeding: a systematic review and meta-analysis. 2017 , 29, 621-628	6
613	Direct-acting antivirals: the endgame for hepatitis C?. 2017 , 24, 31-37	62
612	Assessment of liver fibrosis with acoustic radiation force impulse imaging versus liver histology in patients with chronic hepatitis C: a pilot study. 2017 , 29, 951-955	6
611	Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. 2017 , 77, 1043-1055	31
610	Duodenal histopathology and laboratory deficiencies related to bone metabolism in coeliac disease. 2017 , 29, 897-903	12
609	Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience. 2017 , 29, 979-980	10
608	Nonalcoholic fatty liver disease can be predicted by retinal vascular changes in patients with obesity without hypertension or diabetes. 2017 , 29, 962-967	3
607	Management of different types of gastric varices with band ligation: a 3-year experience. 2017 , 29, 968-972	2
606	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. 2017 , 57, 58-68	10
605	Clinical experience and diagnostic algorithm of vulval Crohn's disease. 2017 , 29, 838-843	16
604	Literature review: impacts of socioeconomic status on the risk of inflammatory bowel disease and its outcomes. 2017 , 29, 879-884	13
603	A fixed-dose combination of ledipasvir and sofosbuvir + ribavirin for treatment of hepatitis C infection: a systematic review and meta-analysis. 2017 , 33, 348-360	
602	Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. 2017 , 101, 933-937	13

601	The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. 2017 , 101, 987-995	16
600	Small-bowel mucosal healing assessment by capsule endoscopy as a predictor of long-term clinical remission in patients with Crohn's disease: a systematic review and meta-analysis. 2017 , 29, 844-848	23
599	Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease. 2017 , 93, 92-98	36
598	Interferon-free antiviral therapy for chronic hepatitis C among patients in the liver transplant setting. 2017 , 31, 219-225	6
597	Genetic and environmental factors significant for the presentation and development of inflammatory bowel disease. 2017 , 29, 909-915	11
596	Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral Agents. 2017 , 101, 1704-1710	61
595	NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. 2017 , 52, 845-854	40
594	Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. 2017 , 66, 703-710	72
593	Orthotopic liver transplantation changes the course of gastric antral vascular ectasia: a case series from a transplant center. 2017 , 29, 973-976	5
592	Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. 2017 , 16, S1-S23	24
591	Development a validated highly sensitive LC-MS/MS method for simultaneous quantification of Ledipasvir, sofosbuvir and its major metabolite GS-331007 in human plasma: Application to a human pharmacokinetic study. 2017 , 143, 305-310	37
590	Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017 , 42, 621-623	2.2 3
589	Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease. 2017 , 112, 1400-1409	20
588	Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C. 2017 , 24, 966-975	16
587	Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study. 2017 , 29, 777-780	11
586	Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B. 2017 , 29, 946-950	4
585	Effectiveness and safety of ledipasvir/sofosbuvir-ribavirin in the treatment of HCV infection: The real-world HARVEST study. 2017 , 62, 387-392	18
584	Confluence of Epidemics of Hepatitis C, Diabetes, Obesity, and Chronic Kidney Disease in the United States Population. 2017 , 15, 1957-1964.e7	26

583	HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. 2017 , 18, 126-134	29
582	Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease. 2017 , 65, 864-866	7
581	Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing. 2017 , 7, 45605	12
580	Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES. 2017 , 65, 64-72	23
579	Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study. 2017 , 66, 784-793	46
578	Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. 2017 , 29, 826-830	13
577	Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV. 2017 , 10, 583-594	14
576	The prevalence of viral agents in esophageal adenocarcinoma and Barrett's esophagus: a systematic review. 2017 , 29, 817-825	20
575	Clinical usefulness of controlled attenuation parameter to screen hepatic steatosis for potential donor of living donor liver transplant. 2017 , 29, 805-810	14
574	Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort. 2017 , 75, 97-107	26
573	Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients. 2017 , 29, 686-693	39
572	Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach. 2017 , 49, 778-781	8
571	Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?. 2017 , 37, 109-118	59
570	Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. 2017 , 129, 476-483	13
569	Treatment optimization for HIV/HCV co-infected patients. 2017 , 4, 18-36	13
568	Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. 2017 , 49, 561-575	11
567	Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. 2017 , 166, 637-648	383
566	Global epidemiology and burden of HCV infection and HCV-related disease. 2017 , 14, 122-132	233

565	The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. 2017 , 66, 371-378	113
564	Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation. 2017 , 47, 1147-1154	2
563	Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients. 2017 , 36, 853-861	4
562	The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir. 2017 , 11, 103-113	5
561	Urgency to treat patients with chronic hepatitis C in Asia. 2017 , 32, 966-974	18
560	Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. 2017 , 55, 56-71	19
559	NS5A inhibitors for the treatment of hepatitis C infection. 2017 , 24, 180-186	20
558	Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis. 2017 , 37, 982-994	14
557	The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. 2017 , 45, 455-467	15
556	Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. 2017 , 24, 454-463	37
555	Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015). 2017 , 27, 401-414	7
554	Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. 2017 , 47, 1127-1136	27
553	Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey. 2017 , 11, 509-516	3
552	Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. 2017 , 46, 711-721	40
551	Utilization of the Iliac Artery as Inflow in the Morbidly Obese During Orthotopic Liver Transplantation: A Case Report. 2017 , 49, 1624-1627	
550	The potential of signal peptide peptidase as a therapeutic target for hepatitis C. 2017 , 21, 827-836	2
549	In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6. 2017 , 22, 587-597	23
548	Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis. 2017 , 49, 1855-1863	8

547	Primer on Hepatitis C Virus Resistance to Direct-Acting Antiviral Treatment: A Practical Approach for the Treating Physician. 2017 , 21, 659-672	4
546	Detectable Viremia at the End of Treatment With Direct-Acting Antivirals Can Be Associated With Subsequent Clinical Cure in Patients With Chronic Hepatitis C: A Case Series. 2017 , 153, 1165-1166	6
545	Experience in real clinical practice with new direct acting antivirals in chronic hepatitis C. 2017 , 149, 375-382	2
544	Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. 2017 , 40, 433-446	
543	Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. 2017 , 40, 433-446	12
542	Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. 2017 , 20, 1110-1120	11
541	Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States. 2017 , 6, 423-433	11
540	Mechanisms involved in liver damage resolution after hepatitis C virus clearance. 2017 , 19, 100-107	4
539	The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. 2017 , 1, 538-549	30
538	Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study. 2017 , 96, e7568	24
537	Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C. 2017 , 29, 767-776	13
536	Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity. 2017 , 96, e5914	38
535	Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. 2017 , 96, e6128	30
534	Reply to: "Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries". 2017 , 67, 1350-1352	5
533	Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct-acting antivirals. 2017 , 46, 628-629	0
532	The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2LH-chloro-2LEC-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors. 2017 , 27, 4323-4330	21
531	Single-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men. 2017 , 10, 480-486	1
530	Hepatitis C Virus Therapy for Decompensated and Posttransplant Patients. 2017 , 51, 215-222	3

529	Hepatitis-Viral. 2017 , 32, 65-86	1
528	Experience in real clinical practice with new direct acting antivirals in chronic hepatitis C. 2017 , 149, 375-382	0
527	Recurrent Disease Following Liver Transplantation. 2017 , 1127-1142	
526	Retreatment Options Following HCV Direct Acting Antiviral Failure. 2017 , 9, 389-402	11
525	Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients. 2017 , 112, 1824-1831	15
524	Resistance to DAAs: When to Look and When It Matters. 2017 , 14, 229-237	22
523	Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV). 2017 , 7, 14421	5
522	Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. 2017 , 72, 2850-2856	8
521	Racial-Ethnic Disparities in Uptake of New Hepatitis C Drugs in Medicare. 2017 , 4, 1147-1158	10
520	Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease. 2017 , 9, 262-276	3
519	The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study. 2017 , 17, 162	22
518	The association between implementation strategy use and the uptake of hepatitis C treatment in a national sample. 2017 , 12, 60	38
517	Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis. 2017 , 25, 11	19
516	Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. 2017 , 46, 424-431	24
515	Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. 2018 , 23, 229-238	43
514	Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis. 2017 , 32, 749-755	9
513	Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. 2017 , 24, 22-27	62
512	Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies. 2017 , 64, 44-52	68

511	Successful ledipasvir + sofosbuvir treatment of active synovitis in a rheumatoid arthritis patient with hepatitis C virus-related mixed cryoglobulinemia. 2017 , 27, 917-918	5
510	Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial. 2017 , 166, 109-117	138
509	Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?. 2017 , 6, 65-82	5
508	Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. 2017 , 30, 23-42	7
507	Drugs to Treat Viral Hepatitis. 2017 , 1327-1332.e1	1
506	Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24. 2017 , 73, 1-14	10
505	Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir. 2017 , 10, 41-46	3
504	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. 2017 , 66, 485-493	160
503	The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. 2017 , 65, 426-438	60
502	Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. 2017 , 37, 653-661	11
501	Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C. 2017 , 13, 105-112	13
500	Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocytic Inhibitor of the Hepatitis C Virus NS3 Protease. 2017 , 61,	3
499	Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. 2017 , 389, 1268-1272	25
498	Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. 2017 , 37, 5-18	62
497	Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. 2017 , 33, 11-21	14
496	Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. 2017 , 64, 92-99	14
495	Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection. 2017 , 47, 773-782	3
494	Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. 2017 , 152, 164-175.e4	136

493	Clinical Manifestations of Acute and Chronic Hepatitis. 2017 , 363-374.e4	
492	Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis. 2017 , 52, 26-38	48
491	Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. 2017 , 68, 345-358	47
490	APSA Awardee Submission: Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases. 2017 , 242, 242-249	7
489	Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome. 2017 , 2, 53-59	17
488	Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. 2017 , 89, 284-290	47
487	Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration. 2017 , 32, 1136-1142	24
486	EASL Recommendations on Treatment of Hepatitis C 2016. 2017 , 66, 153-194	821
485	Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele. 2017 , 65, 999-1005	21
484	Hepatitis C. 2017 , 628-698	
483	RE: Steatorrhea, Hyperoxaluria and Colonic Hyperproliferation After Roux-en-Y Gastric Bypass. 2017 , 153, 1166	
482	Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy. 2017 , 16, 366-374	2
481	A Brief Update on the Treatment of Hepatitis C. 2017 ,	
480	Approaches and Considerations for the Successful Treatment of HCV Infection. 2017 ,	
479	Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients. 2017 , 10, 275-281	3
478	Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C. 2017 , 9, 1179559X1771912	
477	Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. 2017 , 4, ofx024	20
476	Hepatitis C treatment: where are we now?. 2017 , 10, 39-52	64

475	Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. 2017 , 18,	20
474	Treatment Options in Hepatitis C. 2017 , 114, 11-21	14
473	Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis. 2017 , 2017, 8186275	4
472	The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis. 2017 , 2017, 6468309	5
471	Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials. 2017 , 13, 477-497	11
470	Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection. 2017 , 56, 787-790	9
469	Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. 2017 , 4, ofw266	10
468	Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany. 2017 , 12, e0169401	18
467	Continuum of hepatitis C care in France: A 20-year cohort study. 2017 , 12, e0183232	3
466	Feasibility of Treating Hepatitis C in a Transient Jail Population. 2017 , 4, ofx142	20
465	[Revealing the characteristics of antiviral agents]. 2017 , 67, 133-142	
464	Hepatitis C Virus Infection Treatment: Recent Advances and New Paradigms in the Treatment Strategies. 2017 ,	1
463	Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis. 2017 , 9, 281-293	1
462	Efficacy and Safety of Direct-acting Antivirals in Hepatitis C Virus-infected Patients Taking Proton Pump Inhibitors. 2017 , 5, 327-334	7
461	Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. 2017 , 23, 3163-3173	16
460	Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil. 2017 , 16, 727-733	26
459	Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism. 2017 , 16, 207-214	17
458	Current Treatment of Chronic Hepatitis C. 2017 , 781-789	1

457	Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service. 2017 , 9, 163-172	1
456	Patterns in Liver-Related Health Outcomes with Hepatitis C Virus Treatments and Health Equity Implications for Decision Makers: A Cohort Analysis of Medicaid Patients. 2017 , 1, 156-164	1
455	Spectrophotometric Methods for Simultaneous Determination of Sofosbuvir and Ledipasvir (HARVONI Tablet): Comparative Study with Two Generic Products. 2017 , 100, 976-984	18
454	Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. 2018 , 16, 1811-1819.e4	16
453	Pan-NS3 protease inhibitors of hepatitis C virus based on an R-elongated pyrazinone scaffold. 2018 , 148, 453-464	5
452	French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes. 2018 , 21, 1218-1225	16
451	Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. 2018 , 67, 2113-2126	18
450	Identification of T cell and B cell epitopes against Indian HCV-genotype-3a for vaccine development- An in silico analysis. 2018 , 53, 63-71	5
449	[Current drug treatment of hepatitis C : Useful therapy algorithms taking into consideration economical aspects]. 2018 , 59, 401-409	1
448	Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. 2018 , 19, 451-456	2
447	Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. 2018 , 50, 569-583	13
446	Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France. 2018 , 25, 1197-1207	22
445	Direct-Acting Antiviral Agents for HCV Infection. 2018 , 8, 1-2	2
444	No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients. 2018 , 16, 927-935	10
443	Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review. 2018 , 13, 775-790	2
442	Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment. 2018 , 12, 133-142	14
441	Host-targeting therapies for hepatitis C virus infection: current developments and future applications. 2018 , 11, 1756284818759483	22
440	EASL Recommendations on Treatment of Hepatitis C 2018. 2018 , 69, 461-511	1079

439	Ledipasvir/sofosbuvir for treatment-naïve and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. 2018 , 12, 126-132	15
438	Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients. 2018 , 24, 524-530	6
437	Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir. 2018 , 57, 1369-1383	12
436	Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort. 2018 , 63, 1454-1462	2
435	Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens. 2018 , 90, 1087-1093	5
434	Antiviral Agents. 2018 , 1551-1567.e6	3
433	Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. 2018 , 62,	16
432	Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. 2018 , 38, 1571-1575	4
431	Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. 2018 , 78, 245-256	14
430	Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. 2018 , 68, 827-838	101
429	All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. 2018 , 68, 32-47	52
428	Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study. 2018 , 30, 368-375	18
427	Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. 2018 , 47, 1001-1011	7
426	Chronic Hepatitis C in Elderly Patients: Current Evidence with Direct-Acting Antivirals. 2018 , 35, 117-122	10
425	The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. 2018 , 47, 838-844	29
424	Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort study. 2018 , 31, 887-899	30
423	Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India. 2018 , 8, 241-249	4
422	Engineered Livers for Infectious Diseases. 2018 , 5, 131-144	28

4 ²¹	Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor. 2018 , 47, 665-673	11
4 ²⁰	The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort. 2018 , 25, 535-542	9
4 ¹⁹	Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. 2018 , 154, 989-997	79
4 ¹⁸	Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam. 2018 , 23, 415-423	14
4 ¹⁷	Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study. 2018 , 17, 235-241	2
4 ¹⁶	Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. 2018 , 66, 1742-1750	20
4 ¹⁵	Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens. 2018 , 217, 1033-1043	19
4 ¹⁴	Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patients. 2018 , 6, E12-E18	6
4 ¹³	Systemic Antivirals in Dermatology. 2018 , 451-470	1
4 ¹²	Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. 2018 , 5, ofy001	27
4 ¹¹	Treatment of HCV in the Department of Corrections in the Era of Oral Medications. 2018 , 24, 127-136	17
4 ¹⁰	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. 2018 , 8, 3199	14
4 ⁰⁹	Impact of hepatitis C virus recombinant form RF1_2k/1b on treatment outcomes within the Georgian national hepatitis C elimination program. 2018 , 48, 36-44	5
4 ⁰⁸	Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV. 2018 , 38, 76-83	29
4 ⁰⁷	Increasing access to thoracic organs from donors infected with hepatitis C: A previous challenge-now an opportunity. 2018 , 37, 681-683	11
4 ⁰⁶	Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan. 2018 , 53, 419-426	18
4 ⁰⁵	Real-world challenges for hepatitis C virus medications: a critical overview. 2018 , 44, 143-160	14
4 ⁰⁴	Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India. 2018 , 8, 7-14	11

403	Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. 2018 , 6, 213-224	16
402	Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT). 2018 , 25, 37-46	4
401	In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. 2018 , 38, 258-265	29
400	Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. 2018 , 25, 228-235	9
399	Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. 2018 , 50, 156-162	4
398	Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. 2018 , 38, 1010-1021	8
397	A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects. 2018 , 7, 641-651	4
396	Implementation of a multidisciplinary, team-based model to treat chronic hepatitis C in the primary care setting: Lessons learned. 2018 , 6, 205-209	7
395	Hepatitis C Screening: From Modeling to Public Health Policy. 2018 , 66, 385-386	9
394	Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. 2018 , 183, 118-126	105
393	Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C. 2018 , 21, 19-26	9
392	Citius, Altius, Fortius: The New Paradigm in the Treatment of Chronic Hepatitis C Disease. 2018 , 66, 464-474	1
391	Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir. 2018 , 25, 126-133	4
390	Chronic Hepatitis. 2018 , 198-210.e5	
389	Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. 2018 , 90, 907-918	13
388	Current and future challenges in HCV: insights from an Italian experts panel. 2018 , 46, 147-163	3
387	Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ~ HIV-1 Co-Infection. 2018 , 38, 239-247	8
386	Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). 2018 , 19, 227-237	9

385	Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV). 2018 , 21, 612-621	5
384	Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives. 2018 , 67, 2430-2448	28
383	Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. 2018 , 47, 259-267	30
382	Management of Chronic Hepatitis C in End-stage Renal Disease. 2018 , 52, 287-294	2
381	Increasing Prevalence of Hepatitis C among Hospitalized Children Is Associated with an Increase in Substance Abuse. 2018 , 192, 159-164	27
380	Direct-acting antiviral agents in the treatment of chronic Hepatitis C - "Real-life" experience from an academic centre and two specialized clinical practices. 2018 , 56, 351-360	3
379	Inpatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens. 2018 , 25, 344-353	3
378	Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. 2018 , 68, 663-671	34
377	Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study. 2018 , 53, 548-556	8
376	Diabetes in a Hepatitis C and HIV-Coinfected Patient Treated With the Ledipasvir and Sofosbuvir Regimen. 2018 , 25, e391	1
375	A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study. 2018 , 25, 56-62	9
374	Safety, Tolerability, and Associated Side Effects of Direct- Acting Antivirals. 2018 ,	
373	Multicenter Experience using Ledipasvir/Sofosbuvir + RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. 2018 , 17, 815-821	4
372	6th Canadian Symposium on Hepatitis C Virus: Delivering a cure for hepatitis C infection—What are the remaining gaps?. 2018 , 1, 94-105	3
371	2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. 2018 , 24, 169-229	24
370	The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors. 2018 , 36, 224-229	6
369	Design and Analysis of a Novel 6-URS Self-Reconfigurable All-Dimensional Walking Robot. 2018 ,	
368	It's been a long haul, a big haul, but we've made it!: hepatitis C virus treatment in post-transplant patients with virus recurrence: An interpretative phenomenological analysis. 2018 , 5, 2055102918792673	

367	Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?. 2018 , 11, 1756284818812358	8
366	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. 2018 , 13, e0209299	7
365	The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. 2018 , 18, 580	1
364	Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain. 2018 , 13, e0208554	12
363	Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. 2018 , 13, e0205186	8
362	Expression of Duplex shRNAs through a Lentiviral Vector against Cellular and Viral Genes Inflicts Sustained Inhibition of Hepatitis C Virus Replication. 2018 , 61, 79-91	1
361	Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA . 2018 , 63, 3480-3486	3
360	Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. 2018 , 6, 1188-1198	14
359	Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir. 2018 , 2, 1172-1178	10
358	Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis. 2018 , 30, 1378-1383	7
357	Expert opinion on the management of hepatitis C infection in Kuwait. 2018 , 10, 117-132	2
356	Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era. 2018 , 285, 55-71	8
355	Automated quality control for a molecular surveillance system. 2018 , 19, 358	2
354	Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection. 2018 , 15, 466-474	11
353	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. 2018 , 8, 13699	20
352	Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting. 2018 , 2018, 4136253	3
351	Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling. 2018 , 32, 461-480	9
350	Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic. 2018 , 34, 690-698	5

349	The Mexican consensus on the treatment of hepatitis C. 2018 , 83, 275-324	9
348	[Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012]. 2018 , 56, 756-838	24
347	Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid. 2018 , 24, 664-676	7
346	Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. 2018 , 68, 2158-2166	50
345	Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis. 2018 , 4, 17	4
344	Pharmacokinetic evaluation of daclatasvir and ledipasvir in healthy volunteers using a validated highly sensitive spectrofluorimetric method. 2018 , 33, 1094-1100	2
343	Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling. 2018 , 9, 1546	34
342	Novel determination of sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS method: Application to a bioequivalence study. 2018 , 32, e4347	10
341	FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals. 2018 , 38, 967-980	2
340	Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population. 2018 , 24, 591-597	5
339	Setting a Public Health Agenda to Support Access to High-Cost Medicines. 2018 , 51-66	
338	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. 2018 , 25, 1429-1437	14
337	Characterization of and Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort. 2018 , 10,	7
336	Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. 2018 , 53, 986-993	15
335	Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. 2018 , 73, 2112-2119	11
334	Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population. 2018 , 133, 452-460	35
333	Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy. 2018 , 10, 33-42	3
332	Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C. 2018 , 2, 884-892	8

331	HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. 2018 , 8, 12469	4
330	Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. 2018 , 8, 12266	10
329	The Mexican consensus on the treatment of hepatitis C. 2018 , 83, 275-324	
328	Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C. 2018 , 9, 103-110	2
327	Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. 2018 , 11, 295-298	29
326	Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. 2018 , 14, 649-657	3
325	Hepatitis C. 2018 , 436-467	
324	Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. 2018 , 13, e0197544	7
323	Daclatasvir and asunaprevir improves health-related quality of life in Japanese patients infected with hepatitis C virus. 2018 , 2, 87-92	6
322	Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. 2018 , 13, e0193112	4
321	Editorial: retreatment of DAA-failures-no problem at all?. 2018 , 47, 1552-1553	
320	Utilizing Clinical Pharmacist Specialist to Manage Hepatitis C Virus Patients on Direct-Acting Antiviral Therapy. 2019 , 32, 655-663	7
319	[Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents]. 2019 , 90, 141-147	5
318	Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. 2019 , 34, 364-369	20
317	Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?. 2019 , 69, 51-63	28
316	A case with acute-on-chronic liver failure receiving liver transplantation during daclatasvir and asunaprevir therapy in chronic hepatitis C patient. 2019 , 7, 371-373	1
315	Provider Attitudes toward the Use of Hepatitis C Virus-Positive Organs in Kidney Transplantation. 2019 , 50, 168-176	5
314	Cognitive impairments in HCV infection: From pathogenesis to neuroimaging. 2019 , 41, 987-1000	5

313	Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. 2019 , 13, 2565-2577	11
312	Ineffective Absorption? Failure of Direct-Acting Therapy for Chronic Hepatitis C in Cirrhotic Patients With Roux-en-Y Gastric Bypass. 2019 , 7, 2324709619858127	
311	Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience. 2019 , 19, 3046-3057	69
310	In Silico Analysis of Hepatitis B Virus Genotype D Subgenotype D1 Circulating in Pakistan, China, and India. 2019 , 15, 1176934319861337	1
309	Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis. 2019 , 26, 1249-1256	10
308	Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016. 2019 , 25, 1236-1242	10
307	Epidemiología, consumo de recursos y costos del manejo médico de la Hepatitis C en Argentina, Colombia, Uruguay y Venezuela. 2019 , 20, 180-190	1
306	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. 2019 , 157, 1506-1517.e1	19
305	Hepatitis C. 2019 , 394, 1451-1466	155
304	The Evolving Landscape of Liver Cirrhosis Management. 2019 ,	
303	Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients. 2019 , 51, 2295-2304	3
302	The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®). 2019 , 237-280	1
301	Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection. 2019 , 20, 230-236	9
300	Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. 2019 , 393, 1319-1329	130
299	Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection. 2019 , 25, 944-950	10
298	Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era. 2019 , 25, 598-609	40
297	Sustained virologic response with 6 weeks or less of direct-acting antiviral therapy for chronic hepatitis C: Experience at a veterans affairs healthcare system. 2019 , 34, 2173-2178	0
296	Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C. 2019 , 2, e194765	18

295	The Discovery of Sofosbuvir: A Liver-Targeted Nucleotide Prodrug for the Treatment and Cure of HCV. 2019 , 141-169	1
294	Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy. 2019 , 39, 539-546	2
293	Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. 2019 , 58, 1237-1263	34
292	Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in Iranian population. 2019 , 43, 594-602	4
291	Favorable outcome with direct-acting antiviral treatment in hepatitis C patients coinfecting with HIV. 2019 , 49, 1076-1082	5
290	A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection. 2019 , 31, 274-283	0
289	Comparing drug interaction frequencies of various hepatitis C treatment regimens among mono-infected patients. 2019 , 18, 601-606	0
288	Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic. 2019 , 18, 304-309	17
287	Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients. 2019 , 26, 980-990	19
286	Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures. 2019 , 39, 354-368	21
285	Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents. 2019 , 90, 141-147	
284	Hepatitis C in 2019: Are We There Yet?. 2019 , 15, 415-419.e1	3
283	Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. 2019 , 2019, 4029541	8
282	Association Between Baseline Creatinine Clearance and Treatment Failure in Patients With Hepatitis C Virus Treated With Ledipasvir and Sofosbuvir. 2019 , 6, ofz087	
281	Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. 2019 , 14, e0214795	21
280	An update on the management of hepatitis C virus and human immunodeficiency virus co-infection. 2019 , 14, 185-195	
279	Peptic Ulcer Disease: A Brief Review of Conventional Therapy and Herbal Treatment Options. 2019 , 8,	74
278	Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events. 2019 , 156, 987-996.e8	66

277	Hepatitis C: Treatment. 2019 , 454-469	
276	Management of HCV Infection After Liver Transplantation. 2019 , 753-764	
275	Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8 week regimen in a real-world setting. 2019 ,	1
274	Factors influencing hepatitis C cure in the era of direct-acting antivirals. 2019 , 42 Suppl 1, 1-7	1
273	The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni® . 2019 , 57-80	0
272	The Evolution of Clinical Trials for Hepatitis C. 2019 , 187-235	
271	When Theory Becomes Reality: Navigating the Ethics of Transplanting Hepatitis C Virus-Positive Livers Into Negative Recipients. 2019 , 14, 131-134	3
270	Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy. 2019 , 14, e0224751	1
269	Real-World Evidence and Hepatitis C. 2019 , 411-427	
268	Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C. 2019 , 53, 147-154	3
267	Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. 2019 , 31, 1049-1056	4
266	Changing epidemiology of chronic hepatitis C: patients are older and at a more advanced stage at the time of diagnosis. 2019 , 31, 1247-1249	1
265	Novel spectrofluorimetric approach for determination of ledipasvir through UV-irradiation: application to biological fluids, pharmacokinetic study and content uniformity test.. 2019 , 9, 34256-34264	10
264	Risks, benefits, and ethical questions associated with transplanting kidneys from hepatitis C virus-infected donors into hepatitis C virus-negative patients. 2019 , 32, 179-186	5
263	Weight loss changed gait kinematics in individuals with obesity and knee pain. 2019 , 68, 461-465	18
262	The Effectiveness of Ledipasvir/Sofosbuvir in Youth With Genotype 4 Hepatitis C Virus: A Single Egyptian Center Study. 2019 , 38, 22-25	8
261	Hepatitis C virus therapy: No one will be left behind. 2019 , 53, 755-760	17
260	Hepatitis C virus direct-acting antiviral nonadherence: Relationship to sustained virologic response and identification of at-risk patients. 2019 , 59, 51-56	4

259	Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. 2019 , 259, 54-61	4
258	Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance. 2019 , 57,	13
257	Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study. 2019 , 49, 125-135	11
256	Evolution of efficacious pangenotypic hepatitis C virus therapies. 2019 , 39, 1091-1136	10
255	Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development. 2019 , 208, 3-24	11
254	Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. 2019 , 68, 721-728	22
253	Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis. 2019 , 9, 4-12	4
252	Using telehealth to improve access to hepatitis C treatment in the direct-acting antiviral therapy era. 2020 , 26, 180-185	6
251	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. 2020 , 53, 569-577	14
250	Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients. 2020 , 15, 53-60	1
249	Provider Perceptions of Hepatitis C Treatment Adherence and Initiation. 2020 , 65, 1324-1333	8
248	Long-term morbidity and mortality in a Canadian post-transfusion hepatitis C cohort: Over 15 years of follow-up. 2020 , 27, 235-242	1
247	Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies. 2020 , 27, 243-260	10
246	Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. 2020 , 119, 712-719	2
245	Efficacy of Direct-Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States. 2020 , 68, 379-387	6
244	Evolution and Revolution of Hepatitis C Management: From Non-A, Non-B Hepatitis Toward Global Elimination. 2020 , 1-6	9
243	Incidence and predictors of direct-acting antiviral treatment failure in Turkish patients with chronic hepatitis C genotype 1b infection. 2020 , 50, 141-146	2
242	The effect of direct antiviral treatment on the depression, anxiety, fatigue and quality-of-life in chronic hepatitis C patients. 2020 , 32, 246-250	4

241	Favorable Sustained Virologic Response Rates Using Direct-Acting Antiviral Therapies at a Large Safety-Net Hospital. 2020 , 31, 1213-1227		
240	Generation of Combinatorial Lentiviral Vectors Expressing Multiple Anti-Hepatitis C Virus shRNAs and Their Validation on a Novel HCV Replicon Double Reporter Cell Line. 2020 , 12,		1
239	Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion. 2020 , 58, 1110-1131		3
238	Association of human immunodeficiency virus and hepatitis C virus infection with long-term outcomes post-ST segment elevation myocardial infarction in a disadvantaged urban community. 2020 , 311, 60-66		1
237	A Focus on Evaluating Major Study Limitations in Order to Apply Clinical Trials to Patient Care: Implications for the Healthcare Team. 2021 , 56, 597-603		
236	Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure. 2020 , 12, 1-14		1
235	Editorial: impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis-a prospective serial follow-up MRI study. 2020 , 52, 735-736		0
234	Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. 2020 , 75, 3303-3310		2
233	Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. 2020 , 222, S745-S757		4
232	Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C. 2020 , 3, e2011055		18
231	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. 2020 , 119, 1019-1040		27
230	Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment. 2020 , 54, 1057-1064		1
229	Changes of inflammatory cytokines/chemokines during ravidasvir plus ritonavir-boosted danoprevir and ribavirin therapy for patients with genotype 1b hepatitis C infection. 2020 , 92, 3516		1
228	The effect of pulsatile pump perfusion on hepatitis C transmission in kidney transplantation: A prospective pilot study. 2020 , 34, e13987		1
227	Contrasting Role of Dose Increase in Modulating Sofosbuvir-Induced Hepatocyte Toxicity. <i>Drug Research</i> , 2020 , 70, 137-144	1.8	1
226	Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfecting with HIV and HCV: Real world data in a black population. 2020 , 99, e19140		
225	Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. 2020 , 20, 47		11
224	Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa. 2020 , 110, 112-117		3

223	Minimal Compared With Standard Monitoring During Sofosbuvir-Based Hepatitis C Treatment: A Randomized Controlled Trial. 2020 , 7, ofaa022	5
222	Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. 2020 , 7, ofaa040	11
221	Micellar-based spectrofluorimetric method for the selective determination of ledipasvir in the presence of sofosbuvir: application to dosage forms and human plasma. 2020 , 35, 486-492	10
220	Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany. 2020 , 17,	1
219	HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. 2020 , 15, e0224875	3
218	Evaluation of a new point-of-care oral anti-HCV test for screening of hepatitis C virus infection. 2020 , 17, 14	12
217	Ombitasvir/paritaprevir/ritonavir & dasabuvir + ribavirin following protease inhibitors failure - a prospective multi-centre trial. 2020 , 20, 264	4
216	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. 2020 , 14, 362-372	5
215	Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens. 2020 , 20, 93	3
214	Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France. 2021 , 66, 881-898	0
213	Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. 2021 , 66, 1315-1326	5
212	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. 2021 , 74, 1053-1063	23
211	The effectiveness and safety of sofosbuvir-ledipasvir for patients with hepatitis C virus genotype 2 infection. 2021 ,	
210	Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan. 2021 , 28, 129-141	2
209	Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. 2021 , 1322, 139-157	2
208	National Hepatitis C Elimination Program of Georgia. 2021 , 237-245	
207	Treatment progress and expansion in Japan: From interferon to direct-acting antiviral. 2021 , 3, 321-334	0
206	Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. 2021 , 121, 3238-3270	12

205	Innovative Thin-Layer Chromatography/Fluorescence Detection Approach for Sensitive and Specific Determination of Ledipasvir in RatsLFeces and Pharmaceutical Dosage Form. 2021 , 59, 634-641	3
204	Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. 2021 , 73, e3349-e3354	3
203	Elevation of Plasminogen Activator Inhibitor-1 promotes differentiation of Cancer Stem-like Cell state by Hepatitis C Virus infection. 2021 ,	1
202	Are Hepatitis C Positive Female Liver Transplant Recipients Still at Increased Risk for Graft Failure? Re-Examining the Disparity in the Modern Era of Direct Acting Antiviral Agents. 2021 ,	
201	Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male Egyptian volunteers. 2021 , 77, 1369-1379	1
200	Viral hepatitis: A brief introduction, review of management, advances and challenges. 2021 , 9, 139-151	
199	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. 2021 , 53, 1603-1609	
198	Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase. 2021 ,	0
197	Blinding in Clinical Trials for Chronic Liver Diseases. 2021 , 41, 163-171	0
196	Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes. 2021 , 77, 739-747.e1	11
195	Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use. 2021 , 133, 641-646	1
194	Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. 2021 , 21, 413	1
193	Analytical Method Development and Validation for the Simultaneous Estimation of Metformin Hydrochloride and Alogliptin by RP-HPLC in Bulk and Tablet Dosage Forms. 2021 , 111-118	3
192	Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?. 2021 , 32, 155-163	
191	Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease. 2021 , 116, 1924-1928	1
190	Efficacy of Direct-Acting Antiviral Combination Therapy in the Treatment of Hepatitis C Virus Among Kidney Transplant Patients. 2021 , 19, 169-173	
189	Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease. 2021 , 2021, 8811203	1
188	High HCV cure rates among people who inject drugs and have suboptimal adherence: A patient-centered approach to HCV models of care. 2021 , 93, 103135	1

187	Follow-Up of Patients Who Achieved Sustained Virologic Response after Interferon-Free Treatment against Hepatitis C Virus: Focus on Older Patients. 2021 , 57,	1
186	An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection. 2021 , 22, 1839-1846	
185	4?-Selenonucleosides: Regio- and Stereoselective Synthesis of Novel Ribavirin and Acadesine Analogs as Anti-Hepatitis C Virus (HCV) Agents.	
184	Machine-learning-based predictions of direct-acting antiviral therapy duration for patients with hepatitis C. 2021 , 154, 104562	2
183	Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study. 2021 , 27, 125-135	1
182	Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. 2019 , 1911, 3-32	52
181	Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. 2018 , 163, 51-56	33
180	Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. 2017 , 553-627	0
179	Harvoni: A Combination Therapy for Curing HCV. 2017 , 558-582	2
178	Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis. 2018 , 30, 296-301	2
177	No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection. 2017 , 24, 808-813	6
176	Hepatitis C Virus. 1599-1616	1
175	Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritransplant Setting: A Case Report. 2016 , 17, 605-10	1
174	ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens. 2015 , 4, 1062	39
173	Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. 2016 , 5,	10
172	Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. 2014 , 9, e110857	13
171	Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication. 2015 , 10, e0119172	10
170	Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent. 2015 , 10, e0122844	31

169	Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. 2015 , 10, e0126984	33
168	Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. 2015 , 10, e0135645	51
167	Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. 2016 , 11, e0155142	8
166	Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. 2017 , 12, e0170933	7
165	Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies. 2015 , 3, 36-41	7
164	Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review. 2015 , 3, 140-8	23
163	Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. 2015 , 3, 42-4	5
162	Canadian Association of General Surgeons position statement: recommendations for surgeons with blood-borne communicable diseases. 2016 , 59, 83-6	0
161	Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA). 2015 , 1, 009-017	2
160	Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature. 2017 , 8, 22299-22303	7
159	Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. 2018 , 9, 5509-5513	5
158	Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases. 2015 , 6, 20327-44	17
157	Treating hepatitis C - what's new?. 2015 , 38, 191-7	5
156	Ledipasvir with sofosbuvir. 2015 , 38, 219-21	4
155	Hepatitis C Virus: Efficacy of New DAAs Regimens. 2020 , 20, 143-149	12
154	KASL clinical practice guidelines: management of hepatitis C. 2016 , 22, 76-139	58
153	Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL. 2018 , 24, 278-293	11
152	Therapy Implications of Hepatitis C Virus Genetic Diversity. 2020 , 13,	13

151	Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. 2015 , 21, 7412-26	35
150	Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. 2015 , 21, 10749-59	19
149	Impact of new treatment options for hepatitis C virus infection in liver transplantation. 2015 , 21, 10760-75	23
148	Diabetes mellitus and metformin in hepatocellular carcinoma. 2016 , 22, 6100-13	44
147	Pleiotropic effects of statins in the diseases of the liver. 2016 , 22, 6201-13	33
146	Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance. 2016 , 22, 6573-81	20
145	Retrospective analysis of hepatitis C infected patients treated through an integrated care model. 2016 , 22, 8558-8567	5
144	Alcoholic liver disease and hepatitis C virus infection. 2016 , 22, 1411-20	28
143	Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon. 2016 , 22, 1650-63	34
142	Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection. 2016 , 22, 9044-9056	6
141	Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. 2016 , 22, 2844-54	4
140	Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. 2017 , 23, 8120-8127	6
139	Exploring the hepatitis C virus genome using single molecule real-time sequencing. 2019 , 25, 4661-4672	9
138	Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. 2019 , 25, 6551-6560	10
137	Liver-related effects of chronic hepatitis C antiviral treatment. 2020 , 26, 2931-2947	5
136	Updated Treatment of Chronic Hepatitis C. 2017 , 92, 24-35	6
135	The new era of hepatitis C virus therapy. 2015 , 21, 345-54	2
134	SASLT guidelines: Update in treatment of Hepatitis C virus infection. 2016 , 22 Suppl, S25-57	15

133	Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. 2017 , 146, 23-33	11
132	Effectiveness of Treatment of Chronic Viral Hepatitis C by Direct-Acting Antivirals in Togo. 2019 , 09, 125-133	2
131	Era of direct acting anti-viral agents for the treatment of hepatitis C. 2018 , 10, 670-684	16
130	Predictive factors associated with hepatitis C antiviral therapy response. 2015 , 7, 1617-31	58
129	Hepatitis C: Treatment of difficult to treat patients. 2015 , 7, 1953-63	17
128	New treatment strategies for hepatitis C infection. 2015 , 7, 2100-9	18
127	All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. 2015 , 7, 2363-8	10
126	Era of direct acting antivirals in chronic hepatitis C: Who will benefit?. 2015 , 7, 2543-50	8
125	Update on hepatitis C: Direct-acting antivirals. 2015 , 7, 2829-33	18
124	Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. 2015 , 7, 725-37	42
123	Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. 2015 , 7, 806-13	42
122	Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. 2015 , 7, 1133-41	18
121	Sofosbuvir/velpatasvir: A promising combination. 2016 , 8, 785-9	11
120	Chronic hepatitis C: This and the new era of treatment. 2016 , 8, 92-106	57
119	Sofosbuvir treatment and hepatitis C virus infection. 2016 , 8, 183-90	11
118	Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment. 2016 , 8, 1318-1326	17
117	Is the 25-year hepatitis C marathon coming to an end to declare victory?. 2017 , 9, 921-929	5
116	Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin. 2017 , 9, 161-166	7

115	Safety and efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in hepatitis C virus/human immunodeficiency virus co-infected patients. 2017 , 9, 1190-1196	1
114	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. 2017 , 9, 352-367	37
113	Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C. 2016 , 10, 808-17	2
112	Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis. 2017 , 11, 335-348	12
111	Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients. 2017 , 11, 711-720	5
110	Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced. 2017 , 11, 721-727	9
109	Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting. 2018 , 12, 694-703	13
108	Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. 2020 , 31, 148-155	2
107	Use of eltrombopag in thrombocytopenia of liver disease. 2014 , 3, 186	1
106	Perspective of antiviral therapeutics for hepatitis C after liver transplantation. 2014 , 3, 193	3
105	Efficacy and Safety of Generic Sofosbuvir/Ledipasvir Fixed-Dose Combination in Iranian Patients with Chronic Hepatitis C Virus Infection. 2017 , 17,	10
104	Occult Hepatitis C Infection Should Be More Noticed With New Treatment Strategies. 2015 , 15, e33462	6
103	Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. 2016 , 16, e37089	51
102	Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict Rules. 2019 , In Press,	0
101	Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience. 2018 , 18,	2
100	Incidence of Post-Liver Transplant Hepatic Dysfunction After Sustained Virologic Response Following Direct-Acting Anti-Hepatitis C Therapy. 2020 , 18, 345-352	1
99	Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation. 2021 ,	5
98	Ubiquitin-Proteasome Pathway, Alcohol and Hepatitis C Infection (HCV). 2014 , 1,	

- 97 Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management. **2014**, 2, 189-96 2
- 96 Hepatitis C Virus Infection: A New Era. **2015**, 1-8
- 95 Ribavirin-free treatment may soon be a reality. **2015**, 21, 260-1 2
- 94 Neue Arzneimittel 2014. **2015**, 37-198 3
- 93 Hepatitis C Virus Infection. **2015**, I-2-12-I-2-15
- 92 Hepatitis C Virus Infection. 1939-1957
- 91 Hepatitis C Virus Infection: A New Era. **2016**, 1-8
- 90 Treatment of Recurrent Hepatitis C. **2016**, 55-77
- 89 . **2016**, 14,
- 88 Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. **2016**, 4, 97-112 4
- 87 Current and Emerging Therapeutic Regimens for Patients with Chronic Hepatitis C Infection. **2016**, 3, 58-69
- 86 Newest approaches for the treatment of Hepatitis C, is there a real chance of curing it?. **2016**, 12, 93-97
- 85 A real-world intention-to-treat analysis of a decades experience of treatment of hepatitis C with interferon-based therapies. **2016**, 5, 2061 1
- 84 New era of liver transplantation for HIV-HCV Co-infected patients: A case report. **2017**, 1, 072-076
- 83 Quasispecies and Drug Resistance. **2017**, 123-147 1
- 82 Relapse of HCV Genotype 1b Infection After Sofosbuvir/Ledipasvir Treatment Presenting as De Novo Cryoglobulinemic Vasculitis. **2017**, 4, e21
- 81 Is the 25-year hepatitis C marathon coming to an end to declare victory?.
- 80 Sofosbuvir-Velpatasvir-Voxilaprevir for Chronic Hepatitis C - A Review. **2017**, 7,

79	. 2017 , 15,	
78	Treatment of Hepatitis C. 2018 , 446-463.e3	
77	Chronische Hepatitis. 2018 , 433-445	
76	Liver Stiffness Measurement Is Useful to Predict Early Recurrence of Hepatocellular Carcinoma after Sustained Virological Responses by Direct Antiviral Agents in Patients with Hepatitis C. 2018 , 08, 255-268	
75	Predictors of functional benefit of hepatitis C therapy in a Real-life Cohort. 2018 , 24, 852-861	2
74	The Real-World Efficacy and Safety of Direct-Acting Oral Antiviral Treatment in Chronic Hepatitis C Genotype 1 Patients in Turkey. 768-776	1
73	Hepatitis C Virus - Related Hepatocellular Carcinoma in the Era of Direct - Acting Antiviral Agents. 2018 , 18,	0
72	Expanding care for patients infected with Hepatitis C through community partnership in Delaware. 2018 , 4, 76-79	1
71	Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review. 2018 , In Press,	0
70	Antifibrotic Therapy for Liver Cirrhosis. 2019 , 167-189	
69	Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. 2019 , 25, 3897-3919	1
68	Ombitasvir/Paritaprevir/Ritonavir & Dasabuvir ± Ribavirin following protease inhibitors failure - A Prospective Multi-Centre Trial.	
67	Recapture of patients with an incomplete diagnosis of hepatitis C virus infection. 2020 , 112, 525-531	1
66	Prevalence and detection of undiagnosed active hepatitis C virus infections in Navarre, Spain, 2017-2019. 2021 , 113, 28-34	0
65	Efficacy of Posttransplant Ledipasvir-Sofosbuvir in the Treatment of Patients Who Have Undergone Chronic Hepatitis C-Related Liver Transplant. 2020 ,	0
64	Real-life experience of ledipasvir and sofosbuvir single-tablet regimen among chronic hepatitis C patients in Turkey. 2020 , 31, 239-245	1
63	Hepatitis C: How Good Are Real-Life Data and Do Generics Work. 2020 , 49, 279-299	
62	Predictive Factors Differ between Hepatocellular Carcinoma Occurrence and Recurrence after Sustained Virological Responses by Direct-Acting Antivirals in Patients with Hepatitis C. 2020 , 10, 1-13	

- 61 Ombitasvir/Paritaprevir/Ritonavir & Dasabuvir – Ribavirin following protease inhibitors failure - A Prospective Multi-Centre Trial.
- 60 Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. **2021**, 72, 780-786 2
- 59 Is ribavirin alive or dead in the current era of HCV therapy?. **2020**, 35-40
- 58 Morbid obesity and hepatitis C: treat as normal or are there additional issues to consider?. **2020**, 59-65
- 57 Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection. **2014**, 39, 345-52 11
- 56 Sofosbuvir: a novel oral agent for chronic hepatitis C. **2014**, 27, 331-337 56
- 55 A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver □ April 9-13, 2014 □ London, United Kingdom Special Reporting on: □ SAPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in Treatment-Experienced Adults With Hepatitis C Virus Genotype 1 □ All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without. **2014**, 10, 1-19 44
- 54 Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. **2015**, 40, 256-76 36
- 53 Hepatitis C (chronic). **2015**, 2015,
- 52 A SPECIAL MEETING REVIEW EDITION: Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting: A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 □ Boston, Massachusetts Special Reporting on: □ Evaluation of Sofosbuvir and Simvastatin-Based Regimen in the TROPIC-1 Trial for Treatment of Non-STAT-Created Patients. **2014**, 10, 1-19 19
- 51 A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver □ April 22-26, 2015 □ Vienna, Austria Special Reporting on: □ Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection. **2015**, 11, 458-66 85
- 50 with Child-Pugh Class B Cirrho. **2015**, 11, 1-23 11
- 49 HCV cure for everyone or which challenges remain?. **2015**, 1, 55-8 1
- 48 Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection. **2015**, 11, 294-346 4
- 47 A Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Hepatitis C Virus Genotype 1. **2014**, 10, 815-7 3
- 46 The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations. **2016**, 12, 1-11 5
- 45 New Therapies for Hepatitis C Virus Infection. **2017**, 13, 22-31 12
- 44 Hepatitis C in a New Era: A Review of Current Therapies. **2017**, 42, 316-329 28

43	Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders. 2017 , 13, 587-595	7
42	Improving HCV cure rates in HIV-coinfected patients - a real-world perspective. 2016 , 22, SP198-204	8
41	Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care. 2014 , 22, 685-9	1
40	CROI 2015: Highlights of Viral Hepatitis Therapy. 2015 , 23, 66-76	1
39	Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital. 2018 , 31, 226-236	4
38	Genotypic resistance testing of HCV - is there a clinical need?. 2016 , 4, Doc05	
37	New Treatments for Hepatitis C. 2015 , 32, 25S-31S	
36	Paronychia Associated with Ledipasvir/Sofosbuvir for Hepatitis C Treatment. 2019 , 12, 35-37	
35	Significant HbA Lowering in Patients Achieving a Hepatitis C Virus Cure. 2019 , 36, S26-S32	2
34	Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C. 2019 , 32, 296-302	
33	Depressive and Anxious Symptoms in Hepatitis C Virus Infected Patients Receiving DAA-Based Therapy.. 2021 , 11,	1
32	A Novel Imidazolinone Derivative with 5-arylidene and 2- Substituted Mercapto Group as Potent Anti-Hepatitis C Virus Compound.. 2021 , e202100602	0
31	Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response.. 2022 , 14, 62-79	0
30	Insights Into the Coinfections of Human Immunodeficiency Virus-Hepatitis B Virus, Human Immunodeficiency Virus-Hepatitis C Virus, and Hepatitis B Virus-Hepatitis C Virus: Prevalence, Risk Factors, Pathogenesis, Diagnosis, and Treatment.. 2021 , 12, 780887	1
29	Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt-case study.. 2021 , 14, 106	1
28	Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure.. 2022 , 11,	1
27	Preferred Therapy for Specific Viral Pathogens. 2022 , 173-189	
26	Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users.. 2022 , 58,	0

- 25 Efficacy and Safety of Direct-Acting Antiviral Therapy for Hepatitis C Virus in Elderly Patients (≥65 years old): A Systematic Review and Meta-Analysis.. **2022**,
- 24 Assessing the potential cost-effectiveness of centralized vs point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison.
- 23 Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario: A cross-sectional study.. **2022**, 48, 179-180
- 22 The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments.. **2022**, 23, 354 1
- 21 The curing regimens of HCV: A SWOT analysis.. **2022**, 27, 13596535211072672 0
- 20 Revolution in the diagnosis and management of hepatitis C virus infection in current era. **2022**, 14, 647-669 0
- 19 Breakthroughs in hepatitis C research: from discovery to cure. 5
- 18 Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein. *Drug Research*, 1.8
- 17 Surveillance of hepatocellular carcinoma using liver stiffness in patients with hepatitis C after sustained virologic response by direct-acting antivirals. *Acta Hepatologica Japonica*, **2022**, 63, 268-278 0.3
- 16 Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis. *Journal of Clinical Pharmacy and Therapeutics*, 2.2
- 15 Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. *Frontiers in Pharmacology*, 13, 5.6 0
- 14 Hepatitis C virus, insulin resistance, and diabetes: A review. 1
- 13 HBV Genomic Integration and Hepatocellular Carcinoma. **2022**, 2022, 1-7 0
- 12 Impact of an Accelerated Pretreatment Evaluation on Linkage-to-Care for Hepatitis C-infected Persons Who Inject Drugs. **2022**, 16, 117822182211190 0
- 11 Hepatitis C. **2022**, 0
- 10 Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal. 0
- 9 Antiviral Agents. **2023**, 1583-1598.e6 0
- 8 Sustained virological response (SVR) and safety of two direct acting anti-viral (DAA) combination therapies in Chronic Hepatitis-C infected patients of Lahore, Pakistan. A Randomized Controlled Trial. 135-139 0

- 7 When art and science collide: The 2022 guidelines for the care of heart transplant recipients. **2022**, ○
- 6 Quercetin: A Functional Food-Flavonoid Incredibly Attenuates Emerging and Re-Emerging Viral Infections through Immunomodulatory Actions. **2023**, 28, 938 1
- 5 Current Landscape of HCV Therapeutics. **2023**, 142-174 ○
- 4 Peer recovery coaching for comprehensive HIV, hepatitis C, and opioid use disorder management: The CHORUS pilot study. **2023**, 7, 100156 ○
- 3 Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. 29, 949-966 ○
- 2 Preferred Therapy for Specific Viral Pathogens. **2023**, ○
- 1 Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus. **2023**, 15, 981 ○